.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 9,283,282

« Back to Dashboard

Claims for Patent: 9,283,282

Title:Sustained release polymer
Abstract: A polymer and a method for its preparation are provided. The polymer comprises poly(lactide), poly(lactide/glycolide) or poly(lactic acid/glycolic acid) segments bonded by ester linkages to both ends of an alkanediol core unit. The polymer is for use in a controlled release formulation for a medicament, preferably leuprolide acetate. The controlled release formulation is administered to a patient as a subcutaneous depot of a flowable composition comprising the polymer, a biocompatible solvent, and the medicament. Controlled release formulations comprising the polymer release leuprolide for treatment of prostate cancer patients over periods of 3-6 months.
Inventor(s): Dunn; Richard L. (Fort Collins, CO)
Assignee: Tolmar Therapeutics, Inc. (Fort Collins, CO)
Application Number:14/463,353
Patent Claims: 1. A composition suitable for treatment of prostate cancer, comprising a polyester, N-methyl pyrrolidone and leuprolide acetate, wherein the polyester comprises two poly(lactide-co-glycolide) segments covalently bonded through their terminal carboxyl groups to 1,6-hexane diol as a core unit so that the polyester is PLG-COO--(CH.sub.2).sub.6--OOC-PLG.

2. A composition according to claim 1 wherein the ratio of lactide to glycolide in the segments is 85/15 or 75/25.

3. A composition according to claim 2 wherein the inherent viscosity of the polyester is about 0.23-0.31 dL/gm or about 0.25 dL/gm or about 0.27 dL/gm.

4. A dosage form of a composition of claim 1 wherein the polyester and N-methyl pyrrolidone are contained in a first syringe and lyophilized leuprolide acetate is contained in a second syringe, the first and second syringes being capable of coupling together to enable mixing of the polyester, N-methyl pyrrolidone and leuprolide acetate.

5. A dosage form of a composition of claim 1 wherein the combination of the polyester and N-methyl pyrrolidone comprises a total weight of about 550 mg with 50 wt % being the polyester, and the leuprolide acetate comprises a weight of about 73 to 74 mg.

6. A dosage form of a composition of claim 1 comprising about 0.375 ml total volume with about 45 mg of leuprolide acetate, about 165 mg polyester and about 165 mg N-methyl pyrrolidone.

7. A dosage form of a composition of claim 1 comprising about 0.5 ml total volume with about 30 mg leuprolide acetate, about 211.5 mg polyester and about 258.5 mg N-methyl pyrrolidone.

8. A dosage form of a composition of claim 1 comprising about 0.375 ml total volume with about 22.5 mg leuprolide acetate, about 159 mg polyester and about 194 mg N-methyl pyrrolidone.

9. A dosage form of a composition of claim 2 wherein the polyester and N-methyl pyrrolidone are contained in a first syringe and lyophilized leuprolide acetate is contained in a second syringe, the first and second syringes being capable of coupling together to enable mixing of the polyester, N-methyl pyrrolidone and leuprolide acetate.

10. A dosage form of a composition of claim 2 wherein the combination of the polyester and N-methyl pyrrolidone comprise a total weight of about 550 mg with 50 wt % being the polyester, and the leuprolide acetate comprises a weight of about 73 to 74 mg.

11. A dosage form of a composition of claim 2 comprising about 0.375 ml total volume with about 45 mg of leuprolide acetate, about 165 mg polyester and about 165 mg N-methyl pyrrolidone.

12. A dosage form of a composition of claim 2 comprising about 0.5 ml total volume with about 30 mg leuprolide acetate, about 211.5 mg polyester and about 258.5 mg N-methyl pyrrolidone.

13. A dosage form of a composition of claim 2 comprising about 0.375 ml total volume with about 22.5 mg leuprolide acetate, about 159 mg polyester and about 194 mg N-methyl pyrrolidone.

14. A dosage form of a composition of claim 3 wherein the polyester and N-methyl pyrrolidone are contained in a first syringe and lyophilized leuprolide acetate is contained in a second syringe, the first and second syringes being capable of coupling together to enable mixing of the polyester, N-methyl pyrrolidone and leuprolide acetate.

15. A dosage form of a composition of claim 3 wherein the combination of the polyester and N-methyl pyrrolidone comprise a total weight of about 550 mg with 50 wt % being the polyester, and the leuprolide acetate comprises a weight of about 73 to 74 mg.

16. A dosage form of a composition of claim 3 comprising about 0.375 ml total volume with about 45 mg of leuprolide acetate, about 165 mg polyester and about 165 mg N-methyl pyrrolidone.

17. A dosage form of a composition of claim 3 comprising about 0.5 ml total volume with about 30 mg leuprolide acetate, about 211.5 mg polyester and about 258.5 mg N-methyl pyrrolidone.

18. A dosage form of a composition of claim 3 comprising about 0.375 ml total volume with about 22.5 mg leuprolide acetate, about 159 mg polyester and about 194 mg N-methyl pyrrolidone.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc